Fate Therapeutics Reports First Quarter 2022 Financial Results and Highlights Operational Progress
May 04, 2022 16:01 ET
|
Fate Therapeutics, Inc.
FT596+R Enrollment Ongoing in Single- and Multi-dose, Multi-cycle Cohorts for R/R BCL FT596+R-CHOP Clinical Protocol for First-line Investigation to be Submitted to FDA in 2Q22 FT819 Enrollment...
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2022 Financial Results
April 22, 2022 08:00 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, April 22, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development...
Fate Therapeutics to Present at Upcoming March Investor Conferences
March 02, 2022 16:01 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, March 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development...
Fate Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Operational Progress
February 28, 2022 16:01 ET
|
Fate Therapeutics, Inc.
Enrollment Ongoing in Multi-dose, Multi-cycle Escalation Cohort of FT596+R at 900 Million Cells per Dose for R/R BCL; Interim Phase 1 Data of 16 Patients Showed 69% ORR and 56% CR in Single-dose...
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2021 Financial Results
February 16, 2022 08:00 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of...
Fate Therapeutics to Present at Upcoming February Investor Conferences
February 02, 2022 08:00 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of...
Fate Therapeutics Announces FDA Clearance for FT536, a First-in-class MICA/B-targeted CAR NK Cell Product Candidate for the Treatment of Solid Tumors
January 10, 2022 08:00 ET
|
Fate Therapeutics, Inc.
Multiplexed-engineered CAR NK Cell Product Candidate derived from Clonal Master iPSC Line that incorporates Four Functional Elements, including a Novel CAR Targeting the Pan-tumor Associated Stress...
Fate Therapeutics Showcases Positive Interim Phase 1 Data from FT596 Off-the-shelf, iPSC-derived CAR NK Cell Program for Relapsed / Refractory B-cell Lymphoma at 2021 ASH Annual Meeting
December 13, 2021 16:31 ET
|
Fate Therapeutics, Inc.
5 of 6 Patients Achieve Objective Response, including 4 Patients with Complete Response, with Single Dose of FT596 at 900 Million Cells in Combination with Rituximab 13 of 19 Patients Achieve...
Fate Therapeutics Highlights Positive Durability of Response Data from FT516 Phase 1 Study for B-cell Lymphoma and Announces FDA Regenerative Medicine Advanced Therapy Designation Granted to FT516 for Relapsed / Refractory DLBCL
December 13, 2021 09:01 ET
|
Fate Therapeutics, Inc.
6 of 10 Patients Naïve to Treatment with Autologous CAR T-cell Therapy Continue in Ongoing Response at Median Follow-up of 9.1 Months, including 4 Patients with >6 Months Follow-up, at ≥90 Million...
Fate Therapeutics to Host Virtual Event at the 2021 ASH Annual Meeting
December 08, 2021 17:44 ET
|
Fate Therapeutics, Inc.
SAN DIEGO, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies...